Author:
Li Li,Vashisht Kapil,Boisclair Julie,Li Wenkui,Lin Tsu-han,Schmid Herbert A.,Kluwe William,Schoenfeld Heidi,Hoffmann Peter
Funder
Novartis Pharmaceuticals Canada
Reference22 articles.
1. The regulation of aldosterone synthase expression;Bassett;Mol. Cell. Endocrinol.,2004
2. LCI699, a potent 11beta-hydroxylase inhibitor, normalizes urinary cortisol in patients with Cushing's disease: results from a multicenter, proof-of-concept study;Bertagna;J. Clin. Endocrinol. Metab.,2014
3. Effects of subcutaneous pasireotide on cardiac repolarization in healthy volunteers: a single-center, phase I, randomized, four-way crossover study;Breitschaft;J. Clin. Pharmacol.,2014
4. SOM230: a novel somatostatin peptidomimetic with broad somatotropin release inhibiting factor (SRIF) receptor binding and a unique antisecretory profile;Bruns;Eur. J. Endocrinol.,2002
5. Effects of a novel aldosterone synthase inhibitor for treatment of primary hypertension: results of a randomized, double-blind, placebo- and active-controlled phase 2 trial;Calhoun;Circulation,2011
Cited by
13 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献